PharmAbcine Announces Presentation at the 2017 Annual Meeting of the Society of Neuro-Oncology.
Presentations Will Provide Updates on TTAC-0001(Tanibirumab) phase IIa recurrent GBM trial data in Australia.
Daejeon, Nov. 18, 2017
PharmAbcine, a clinical stage immuno-ocology company, today announced that Dr. Lawrence Cher, MD, PhD., Professor of the University of Melbourne,
and Neuro Oncologist at Austin Health, will provide an update on safety and efficacy interim data from TTAC-0001(Tanibirumab) phase IIa clinical trial
in patients with recurrent glioblastoma (rGBM), the most common and deadly form of brain cancer, at the 22nd Annual Meeting of the Society of
Neuro-Oncology ("SNO") to be held from November 15-19, 2017 in San Francisco, CA.
The title of the presentation of Dr. Cher is "A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)"
About PharmAbcine, Inc.
PharmAbcine is a leading clinical stage biologics company that develops fully human therapeutic antibody (mAb) and next generation multispecific
antibody therapeutics based on in house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology
and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
PharmAbcine`s fully human antibody libraries and innovative selection system are our strong infra. PharmAbcine provide antibody generation service
by using antibody library and selection system. There is co-development opportunity with novel antibody, too.
Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has >300 patients derived cancer stem cell libraries
and its animal model system for evaluating internal pipeline development.
TTAC-0001(=Tanibirumab), anti-KDR neutralizing fully human IgG with unique cross species cross reactivity is completed its Phase IIa recurrent
GBM trial in Australia in August 2017 and its final report will be available at the end of 2017. Perfect molecule to combine
with immune checkpoint blockade is open for out-licensing, co-development and combination clinical trials.
PMC-001(=DIG-KT), next generation bispecific antibody neutralizing both VEGF-KDR and Angiopoietin-TIE2 pathways is superior to Avastin
and Tanibirumab. It also overcome the Avastin resistant brain tumor growth. PMC-002, PMC-003, PMC-004 are derivative molecules from PMC-001.
PMC-201, next generation bispecific antibody neutralizing both VEGF-KDR and Notch-DLL4 pathways overcome anti-cancer drug resistant tumor growth.
PMC-005B, Anti-EGFRviii truly specific fully human IgG with internalization property is perfect for ADC, CAR-T and CAR-NK purpose and is open for codevelopment or out-licensing.
PMC-305, anti-PDL1 fully human antibody interfering PD1-PDL1 pathway.
For more information, please visit www.pharmabcine.com.